An FDA-cleared blood test specific to detecting recent hyperglycemia and hyperglycemic excursions (occurring in the fasting state, postprandial, or both).
Reveals recent trends toward or away from A1C goals, suggesting improving or worsening control.
Is Independently associated with increased rates of diabetes complications.
When used with A1C, provides a more complete assessment of glycemic control to identify patients that may benefit from closer diabetes management.
New studies show GlycoMark is a biomarker of functional pancreatic beta-cell mass in patients at risk for diabetes.
For More Information
The GlycoMark test is FDA cleared for professional use to provide quantitative measurement of 1,5-anhydroglucitol (1,5-AG) in serum or plasma. The GlycoMark test is intended for intermediate-term monitoring of glycemic control in patients with diabetes.